Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Innoviva, Inc. (INVA)
USD21.97
-0.24 (-1.08%)
US NASDAQ Healthcare Biotechnology
Address
1350 Old Bayshore Highway 94010
Burlingame, CA, US
Burlingame, CA, US
CEO
Pavel Raifeld
Website
inva.com
IPO
2004-10-05
CIK 1080014 ISIN US45781M1018
Description
Innoviva, Inc. functions as a pharmaceutical company, concentrating on the worldwide creation and marketing of medical treatments. Its current product lineup prominently includes several once-daily combination therapies: RELVAR/BREO ELLIPTA, which integrates vilanterol (a long-acting beta2 agonist, or LABA) with fluticasone furoate (an inhaled corticosteroid, or ICS); ANORO ELLIPTA, a medication that pairs umeclidinium bromide (a long-acting muscarinic antagonist, or LAMA) with vilanterol (LABA); and TRELEGY ELLIPTA, a comprehensive treatment combining an ICS, LAMA, and LABA. The company has forged a key strategic alliance with Sarissa Capital Management LP. Moreover, Innoviva collaborates with Glaxo Group Limited under an agreement focused on the development and commercialization of daily LABA-based products designed to treat chronic obstructive pulmonary disease and asthma. Founded in 1996, the corporation was initially known as Theravance, Inc., before officially changing its name to Innoviva, Inc. in January 2016. Its primary operational base is situated in Burlingame, California.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD21.97
-0.24 (-1.08%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
775.9K
Beta
0.35
Float Shares
69.57M
Free Float %
108.1%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.62% | -4.13% | -5.22% | +0.36% | +1.08% | +12.66% | +21.01% | +77.74% | +82.05% | +109.49% | +66.04% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (10 ratings, all time)
Buy
Price Targets & DCF
Current price
21.97
Low
32.00
+45.7%
Consensus
40.00
+82.1%
Median
42.00
+91.2%
High
46.00
+109.4%
DCF (Unlevered)
64.86
+195.2%
DCF (Levered)
67.90
+209.0%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
80% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 4 | 0 |
| Hold | 0 | 0 |
| Sell | 1 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | 2 |
33.50
+52.5%
|
| Last Year | 5 |
33.00
+50.2%
|
| All Time | 8 |
30.63
+39.4%
|
Quality scores
Altman Z-Score
3.85
Safe zone
Piotroski F-Score
4 / 9
Average
MOAT Score
5 / 10
Developing
Composite Rating
A+
Overall Score
5 / 5
High
DCF Score
5 / 5
High
ROE Score
5 / 5
High
ROA Score
5 / 5
High
D/E Score
2 / 5
Medium
P/E Score
4 / 5
High
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+18.5% ★ Q1'26: +10.6% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+816.7% ★ Q1'26: +400.0% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+67.3% ★ Q1'26: +35.5% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+80.8% ★ Q1'26: +38.9% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+32.0% ★ Q1'26: +11.4% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+14.3% Q1'26: +35.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.70× ★ Q1'26: 1.72× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2011 actual |
Dec 2012 actual |
Dec 2013 actual |
Dec 2014 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 4 Rev. Ana. 2 EPS Ana. |
Dec 2027 4 Rev. Ana. 2 EPS Ana. |
Dec 2028 4 Rev. Ana. 3 EPS Ana. |
Dec 2029 3 Rev. Ana. 1 EPS Ana. |
Dec 2030 3 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
24.51M
est: 22.47M (+9.1%)
|
5.61M
est: 124.92M (-95.5%)
|
4.53M
est: 4.87M (-7.0%)
|
8.43M
est: 9.47M (-10.9%)
|
53.95M
est: 50.96M (+5.9%)
|
133.57M
est: 132.46M (+0.8%)
|
217.22M
est: 218.53M (-0.6%)
|
261.00M
est: 263.15M (-0.8%)
|
261.02M
est: 257.47M (+1.4%)
|
336.79M
est: 260.58M (+29.2%)
|
391.87M
est: 292.18M (+34.1%)
|
331.34M
est: 337.53M (-1.8%)
|
310.46M
est: 330.50M (-6.1%)
|
358.71M
est: 353.70M (+1.4%)
|
425.13M
est: 399.31M (+6.5%)
|
440.43M
432.44M – 448.43M
+10.3% YoY
|
495.31M
487.71M – 502.89M
+12.5% YoY
|
536.85M
536.48M – 537.23M
+8.4% YoY
|
617.54M
588.24M – 648.94M
+15.0% YoY
|
674.61M
642.60M – 708.91M
+9.2% YoY
|
| EBITDA |
-101.74M
est: -90.99M (-11.8%)
|
-21.90M
est: -22.49M (+2.7%)
|
-149.66M
est: -161.37M (+7.3%)
|
-24.46M
est: -92.16M (+73.5%)
|
45.51M
est: 40.01M (+13.8%)
|
122.94M
est: 104.01M (+18.2%)
|
205.69M
est: 193.53M (+6.3%)
|
248.08M
est: 206.62M (+20.1%)
|
260.23M
est: 202.16M (+28.7%)
|
372.58M
est: 204.61M (+82.1%)
|
464.35M
est: 229.41M (+102.4%)
|
308.32M
est: 157.42M (+95.9%)
|
235.04M
est: 253.07M (-7.1%)
|
85.50M
est: 270.84M (-68.4%)
|
383.79M
est: 305.77M (+25.5%)
|
337.26M
331.14M – 343.38M
+10.3% YoY
|
379.28M
373.46M – 385.09M
+12.5% YoY
|
411.09M
410.80M – 411.38M
+8.4% YoY
|
472.88M
450.44M – 496.92M
+15.0% YoY
|
516.57M
492.06M – 542.84M
+9.2% YoY
|
| EBIT |
-109.32M
est: -98.19M (-11.3%)
|
-13.00M
est: -30.61M (+57.5%)
|
-157.86M
est: -180.35M (+12.5%)
|
-36.64M
est: -68.76M (+46.7%)
|
31.58M
est: 41.66M (-24.2%)
|
108.99M
est: 117.42M (-7.2%)
|
183.60M
est: 186.06M (-1.3%)
|
234.21M
est: 198.24M (+18.1%)
|
246.36M
est: 193.96M (+27.0%)
|
372.58M
est: 196.31M (+89.8%)
|
464.35M
est: 220.11M (+111.0%)
|
302.74M
est: 254.27M (+19.1%)
|
213.26M
est: 236.29M (-9.8%)
|
59.60M
est: 252.88M (-76.4%)
|
343.56M
est: 285.49M (+20.3%)
|
314.90M
309.18M – 320.61M
+10.3% YoY
|
354.13M
348.70M – 359.55M
+12.5% YoY
|
383.83M
383.57M – 384.10M
+8.4% YoY
|
441.53M
420.57M – 463.97M
+15.0% YoY
|
482.32M
459.44M – 506.85M
+9.2% YoY
|
| Net Income |
-115.34M
est: -103.26M (-11.7%)
|
-18.54M
est: -36.36M (+49.0%)
|
-170.70M
est: -181.36M (+5.9%)
|
-168.46M
est: -132.51M (-27.1%)
|
-18.76M
est: -11.16M (-68.2%)
|
59.54M
est: 61.00M (-2.4%)
|
134.14M
est: 131.07M (+2.3%)
|
395.06M
est: 437.17M (-9.6%)
|
157.29M
est: 178.31M (-11.8%)
|
224.40M
est: 205.12M (+9.4%)
|
265.85M
est: 149.86M (+77.4%)
|
213.92M
est: 93.40M (+129.0%)
|
179.72M
|
23.39M
est: 36.10M (-35.2%)
|
271.17M
est: 160.79M (+68.7%)
|
264.78M
261.36M – 268.21M
+64.7% YoY
|
188.56M
184.30M – 208.49M
-28.8% YoY
|
193.29M
151.72M – 201.73M
+2.5% YoY
|
238.18M
223.48M – 253.92M
+23.2% YoY
|
177.15M
166.22M – 188.86M
-25.6% YoY
|
| SGA |
30.68M
est: 4.10M (+647.6%)
|
30.86M
est: 32.09M (-3.8%)
|
24.29M
est: 890.1K (+2,628.8%)
|
34.86M
est: 1.73M (+1,916.1%)
|
19.75M
est: 20.58M (-4.0%)
|
23.19M
est: 26.15M (-11.3%)
|
32.26M
est: 36.23M (-11.0%)
|
17.05M
est: 27.92M (-38.9%)
|
14.66M
est: 16.49M (-11.1%)
|
13.88M
est: 13.34M (+4.1%)
|
16.19M
est: 53.36M (-69.7%)
|
63.54M
est: 32.26M (+97.0%)
|
98.23M
est: 75.23M (+30.6%)
|
115.69M
est: 80.51M (+43.7%)
|
113.17M
est: 90.90M (+24.5%)
|
100.26M
98.44M – 102.08M
+10.3% YoY
|
112.75M
111.02M – 114.48M
+12.5% YoY
|
122.21M
122.12M – 122.29M
+8.4% YoY
|
140.58M
133.91M – 147.72M
+15.0% YoY
|
153.57M
146.28M – 161.37M
+9.2% YoY
|
| EPS |
-1.41
est: -1.15 (-22.6%)
|
-0.20
est: -0.59 (+66.1%)
|
-1.67
est: -2.26 (+25.9%)
|
-1.50
est: -1.00 (-50.0%)
|
-0.16
est: -0.19 (+16.5%)
|
0.54
est: 0.52 (+3.1%)
|
1.25
est: 1.10 (+13.6%)
|
3.92
est: 1.86 (+111.1%)
|
1.56
est: 1.71 (-8.5%)
|
2.21
est: 2.19 (+0.9%)
|
3.24
est: 2.02 (+60.4%)
|
3.07
est: 3.72 (-17.4%)
|
2.92
|
0.37
est: 0.43 (-12.9%)
|
4.02
est: 1.90 (+111.5%)
|
3.13
3.08 – 3.16
+64.8% YoY
|
2.32
2.17 – 2.46
-25.9% YoY
|
2.16
1.79 – 2.38
-7.0% YoY
|
2.81
2.64 – 3.00
+30.1% YoY
|
2.09
1.96 – 2.23
-25.6% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-06 | A+ | 5/5 | 5/5 | 5/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-05-05 | A+ | 5/5 | 5/5 | 5/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-05-04 | A+ | 5/5 | 5/5 | 5/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-05-01 | A+ | 5/5 | 5/5 | 5/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-30 | A+ | 5/5 | 5/5 | 5/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-29 | A+ | 5/5 | 5/5 | 5/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-28 | A+ | 5/5 | 5/5 | 5/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-27 | A+ | 5/5 | 5/5 | 5/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-24 | A+ | 5/5 | 5/5 | 5/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-23 | A | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-22 | A | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-21 | A | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-20 | A | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-17 | A | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-16 | A | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-15 | A | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
181.32M
OE per share TTM
2.14
Owner's Yield
10.86%
Maintenance CapEx ratio
0.22%
Maint CapEx / Avg PPE
0.9%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
63
Total invested
63.79M
Insider transactions (90d)
7
Beneficial owners (>5%)
14
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Abigail P. Johnson | 7.36M | 7.28% | — | — | 7.36M | — | IN | Delaware | 2018-05-10 | ↗ |
| 2 | The Vanguard Group - 23-1945930 | 6.97M | 10.00% | — | 105.3K | 6.81M | 162.7K | IA | Pennsylvania | 2022-07-11 | ↗ |
| 3 | Fidelity Small Cap Discovery Fund | 6.00M | 5.55% | 6.00M | — | — | — | IV | Delaware | 2018-02-13 | ↗ |
| 4 | (1) BlackRock, Inc. | 5.67M | 10.60% | — | — | — | — | HC | Delaware | 2023-01-20 | ↗ |
| 5 | 13-3127734 | 5.30M | 7.62% | 5.15M | — | 5.30M | — | HC | Delaware | 2022-02-11 | ↗ |
| 6 | 26-0385758 | 5.30M | 7.62% | 5.15M | — | 5.30M | — | IA | Delaware | 2022-02-11 | ↗ |
| 7 | 30-0447847 | 4.52M | 7.00% | 4.44M | — | 4.52M | — | IA | Delaware | 2024-02-09 | ↗ |
| 8 | Westfield Capital Management Company, LP | 3.68M | 5.30% | 3.16M | — | 3.68M | — | IA | Massachusetts | 2022-02-01 | ↗ |
| 9 | Innoviva, Inc. | 2.65M | 20.00% | 2.65M | — | 2.65M | 11.00 | CO | — | 2020-04-23 | ↗ |
| 10 | FMR LLC | 1.43M | 1.40% | 550.00 | — | 1.43M | — | HC | Delaware | 2018-08-10 | ↗ |
| 11 | SAK Corporation04-3334541 | 1.01M | 0.92% | — | 1.01M | — | 1.01M | HC | Commonwealth Massachusetts | 2017-05-09 | ↗ |
| 12 | Seth A. Klarman | 1.01M | 0.92% | — | 1.01M | — | 1.01M | HC | Commonwealth Massachusetts | 2017-05-09 | ↗ |
| 13 | The Baupost Group, L.L.C.04-3402144 | 1.01M | 0.92% | — | 1.01M | — | 1.01M | IA | Commonwealth Massachusetts | 2017-05-09 | ↗ |
| 14 | 04-3543039 | 31.3K | 11.00% | — | — | 31.3K | — | IA | Delaware | 2023-02-14 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
63
-217 vs prev Q
New positions
15
Closed positions
231
Increased
35
Reduced
18
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | BLACKROCK, INC. | 10.68M +1.2M (+13.1%) | 213.43M +41.2M (+23.9%) | 15.46% +0.449 pp | 0.00% +0.001 pp | USD19.34 +3.4% | 6 qtrs — |
| 2 | VANGUARD GROUP INC | 7.92M +819.8K (+11.6%) | 158.26M +28.7M (+22.2%) | 11.46% +0.175 pp | 0.00% +0.000 pp | USD14.40 +38.8% | 40 qtrs — |
| 3 | DIMENSIONAL FUND ADVISORS LP | 4.36M +30.0K (+0.7%) | 87.16M +8.1M (+10.3%) | 6.31% -0.574 pp | 0.02% +0.001 pp | USD13.90 +43.8% | 39 qtrs — |
| 4 | RENAISSANCE TECHNOLOGIES LLC | 4.21M -376.8K (-8.2%) | 84.16M +449.8K (+0.5%) | 6.10% -1.200 pp | 0.13% +0.020 pp | USD15.25 +31.1% | 36 qtrs — |
| 5 | SARISSA CAPITAL MANAGEMENT LP | 2.82M +— (+0.0%) | 56.29M +4.9M (+9.5%) | 4.08% -0.402 pp | 25.25% -3.236 pp | USD12.87 +55.3% | 38 qtrs — |
| 6 | STATE STREET CORP | 2.80M +239.8K (+9.4%) | 55.91M +9.2M (+19.8%) | 4.05% -0.017 pp | 0.00% +0.000 pp | USD13.53 +47.7% | 41 qtrs — |
| 7 | ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 2.36M -898.0 (0.0%) | 47.13M +4.1M (+9.5%) | 3.41% -0.338 pp | 0.03% +0.001 pp | USD18.60 +7.5% | 34 qtrs — |
| 8 | AMERICAN CENTURY COMPANIES INC | 2.24M -111.3K (-4.7%) | 44.77M +1.9M (+4.4%) | 3.24% -0.497 pp | 0.02% +0.001 pp | USD18.25 +9.5% | 39 qtrs — |
| 9 | SYSTEMATIC FINANCIAL MANAGEMENT LP | 2.11M -1.8K (-0.1%) | 42.27M +3.6M (+9.4%) | 3.06% -0.305 pp | 1.00% +0.057 pp | USD14.45 +38.3% | 19 qtrs — |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 1.75M +178.2K (+11.3%) | 35.04M +6.3M (+21.9%) | 2.54% +0.034 pp | 0.00% +0.000 pp | USD14.71 +35.9% | 40 qtrs — |
| 11 | MILLENNIUM MANAGEMENT LLC | 1.61M -31.0K (-1.9%) | 32.19M +2.2M (+7.5%) | 2.33% -0.279 pp | 0.01% +0.001 pp | USD18.31 +9.2% | 22 qtrs — |
| 12 | BOSTON PARTNERS | 1.55M +116.8K (+8.2%) | 30.95M +4.8M (+18.5%) | 2.24% -0.035 pp | 0.03% +0.005 pp | USD17.82 +12.2% | 18 qtrs — |
| 13 | BANK OF AMERICA CORP /DE/ | 1.52M +42.6K (+2.9%) | 30.37M +3.4M (+12.7%) | 2.20% -0.149 pp | 0.00% +0.000 pp | USD16.60 +20.4% | 40 qtrs — |
| 14 | MORGAN STANLEY | 1.42M -6.9K (-0.5%) | 28.36M +2.3M (+9.0%) | 2.05% -0.213 pp | 0.00% +0.000 pp | USD17.67 +13.1% | 40 qtrs — |
| 15 | FRANKLIN RESOURCES INC | 1.39M -1.1M (-44.3%) | 27.83M -17.8M (-38.9%) | 2.02% -1.957 pp | 0.01% -0.005 pp | USD15.34 +30.3% | 22 qtrs — |
| 16 | MARSHALL WACE, LLP | 1.39M -260.4K (-15.8%) | 27.81M -2.3M (-7.7%) | 2.01% -0.613 pp | 0.03% -0.005 pp | USD19.47 +2.7% | 10 qtrs — |
| 17 | QUBE RESEARCH & TECHNOLOGIES LTD | 1.22M +192.0K (+18.8%) | 24.30M +5.6M (+30.1%) | 1.76% +0.132 pp | 0.02% +0.005 pp | USD18.26 +9.5% | 8 qtrs — |
| 18 | GOLDMAN SACHS GROUP INC | 1.12M -82.5K (-6.8%) | 22.43M +446.8K (+2.0%) | 1.62% -0.291 pp | 0.00% +0.000 pp | USD16.59 +20.5% | 40 qtrs — |
| 19 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1.02M +147.6K (+16.9%) | 20.41M +4.5M (+28.0%) | 1.48% +0.089 pp | 0.00% +0.001 pp | USD15.79 +26.6% | 40 qtrs — |
| 20 | ROYCE & ASSOCIATES LP | 920.3K +414.4K (+81.9%) | 18.40M +9.2M (+99.3%) | 1.33% +0.528 pp | 0.19% +0.095 pp | USD18.79 +6.4% | 34 qtrs — |
| 21 | MAN GROUP PLC | 850.7K +12.6K (+1.5%) | 17.01M +1.7M (+11.2%) | 1.23% -0.101 pp | 0.03% +0.002 pp | USD16.91 +18.2% | 32 qtrs — |
| 22 | DEUTSCHE BANK AG\ | 849.9K -131.4K (-13.4%) | 16.99M -919.6K (-5.1%) | 1.23% -0.330 pp | 0.01% -0.001 pp | USD16.11 +24.1% | 40 qtrs — |
| 23 | TWO SIGMA INVESTMENTS, LP | 839.9K +317.6K (+60.8%) | 16.79M +7.3M (+76.2%) | 1.22% +0.385 pp | 0.02% +0.010 pp | USD18.23 +9.7% | 18 qtrs — |
| 24 | INVESCO LTD. | 832.6K +67.1K (+8.8%) | 16.64M +2.7M (+19.1%) | 1.21% -0.012 pp | 0.00% +0.000 pp | USD16.15 +23.8% | 40 qtrs — |
| 25 | NORTHERN TRUST CORP | 698.1K -5.7K (-0.8%) | 13.95M +1.1M (+8.7%) | 1.01% -0.109 pp | 0.00% +0.000 pp | USD13.62 +46.8% | 40 qtrs — |
| 26 | DZ BANK AG DEUTSCHE ZENTRAL GENOSSENSCHAFTS BANK, FRANKFURT AM MAIN | 696.9K +246.4K (+54.7%) | 13.93M +5.7M (+69.4%) | 1.01% +0.293 pp | 0.01% +0.005 pp | USD18.87 +5.9% | 16 qtrs — |
| 27 | NUVEEN, LLC | 647.5K -743.8K (-53.5%) | 12.94M -12.4M (-49.0%) | 0.94% -1.276 pp | 0.00% -0.003 pp | USD19.10 +4.7% | 4 qtrs — |
| 28 | BARCLAYS PLC | 588.5K +487.9K (+485.1%) | 11.76M +9.8M (+505.7%) | 0.85% +0.692 pp | 0.00% +0.002 pp | USD19.80 +1.0% | 40 qtrs — |
| 29 | UBS GROUP AG | 508.2K -64.2K (-11.2%) | 10.16M -287.2K (-2.7%) | 0.74% -0.175 pp | 0.00% +0.000 pp | USD17.25 +15.9% | 40 qtrs — |
| 30 | BANK OF NEW YORK MELLON CORP | 483.0K +36.1K (+8.1%) | 9.66M +1.5M (+18.4%) | 0.70% -0.012 pp | 0.00% +0.000 pp | USD13.57 +47.3% | 40 qtrs — |
| 31 | VOLORIDGE INVESTMENT MANAGEMENT, LLC | 481.8K +11.0K (+2.3%) | 9.63M +1.0M (+12.1%) | 0.70% -0.051 pp | 0.03% +0.005 pp | USD19.92 +0.4% | 4 qtrs — |
| 32 | ASSENAGON ASSET MANAGEMENT S.A. | 444.2K +— (+0.0%) | 8.88M +772.9K (+9.5%) | 0.64% -0.063 pp | 0.01% +0.001 pp | USD17.10 +16.9% | 17 qtrs — |
| 33 | RUSSELL INVESTMENTS GROUP, LTD. | 433.2K +49.4K (+12.9%) | 8.66M +1.7M (+23.6%) | 0.63% +0.017 pp | 0.01% +0.002 pp | USD15.25 +31.1% | 24 qtrs — |
| 34 | PACER ADVISORS, INC. | 381.4K -83.2K (-17.9%) | 7.62M -855.7K (-10.1%) | 0.55% -0.187 pp | 0.02% -0.002 pp | USD15.71 +27.2% | 33 qtrs — |
| 35 | D. E. SHAW & CO., INC. | 371.4K -364.3K (-49.5%) | 7.42M -6.0M (-44.7%) | 0.54% -0.633 pp | 0.00% -0.004 pp | USD16.94 +18.0% | 40 qtrs — |
| 36 | AQR CAPITAL MANAGEMENT LLC | 371.1K +68.6K (+22.7%) | 7.42M +1.9M (+34.4%) | 0.54% +0.056 pp | 0.00% +0.000 pp | USD16.42 +21.7% | 35 qtrs — |
| 37 | VICTORY CAPITAL MANAGEMENT INC | 368.0K -143.6K (-28.1%) | 7.36M -2.0M (-21.2%) | 0.53% -0.281 pp | 0.00% -0.001 pp | USD17.81 +12.2% | 36 qtrs — |
| 38 | PRINCIPAL FINANCIAL GROUP INC | 339.1K +49.4K (+17.0%) | 6.78M +1.5M (+28.2%) | 0.49% +0.030 pp | 0.00% +0.001 pp | USD13.14 +52.1% | 40 qtrs — |
| 39 | ALLIANZ ASSET MANAGEMENT GMBH | 336.9K +140.1K (+71.2%) | 6.73M +3.1M (+87.5%) | 0.49% +0.175 pp | 0.01% +0.003 pp | USD19.21 +4.1% | 5 qtrs — |
| 40 | HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | 330.8K +33.9K (+11.4%) | 6.61M +1.2M (+22.0%) | 0.48% +0.007 pp | 0.01% +0.001 pp | USD19.18 +4.2% | 4 qtrs — |
| 41 | HSBC HOLDINGS PLC | 323.6K +323.6K (+100.0%) | 6.43M +6.4M (+100.0%) | 0.47% +0.469 pp | 0.00% +0.003 pp | USD19.99 +0.0% | 1 qtrs NEW |
| 42 | NOMURA HOLDINGS INC | 246.5K +13.4K (+5.7%) | 4.93M +672.7K (+15.8%) | 0.36% -0.014 pp | 0.01% +0.000 pp | USD18.28 +9.4% | 9 qtrs — |
| 43 | PUBLIC SECTOR PENSION INVESTMENT BOARD | 245.8K +12.3K (+5.3%) | 4.91M +652.2K (+15.3%) | 0.36% -0.016 pp | 0.02% +0.001 pp | USD16.63 +20.2% | 37 qtrs — |
| 44 | BALYASNY ASSET MANAGEMENT L.P. | 244.0K +91.5K (+60.0%) | 4.88M +2.1M (+75.3%) | 0.35% +0.111 pp | 0.01% +0.003 pp | USD18.80 +6.3% | 14 qtrs — |
| 45 | LOS ANGELES CAPITAL MANAGEMENT LLC | 253.1K -5.2K (-2.0%) | 4.54M -170.0K (-3.6%) | 0.37% -0.044 pp | 0.02% -0.001 pp | USD17.98 +11.2% | 24 qtrs — |
| 46 | INTECH INVESTMENT MANAGEMENT LLC | 220.2K +183.5K (+499.0%) | 4.40M +3.7M (+556.1%) | 0.32% +0.260 pp | 0.04% +0.033 pp | USD19.60 +2.0% | 7 qtrs — |
| 47 | UNIPLAN INVESTMENT COUNSEL, INC. | 219.5K +28.0K (+14.6%) | 4.39M +893.7K (+25.6%) | 0.32% +0.013 pp | 0.44% +0.098 pp | USD14.69 +36.1% | 10 qtrs — |
| 48 | RHUMBLINE ADVISERS | 199.4K +5.4K (+2.8%) | 3.99M +445.4K (+12.6%) | 0.29% -0.020 pp | 0.00% +0.000 pp | USD14.10 +41.8% | 40 qtrs — |
| 49 | LEGAL & GENERAL GROUP PLC | 190.6K +6.8K (+3.7%) | 3.81M +456.0K (+13.6%) | 0.28% -0.016 pp | 0.00% +0.000 pp | USD14.00 +42.8% | 40 qtrs — |
| 50 | ASSETMARK, INC | 185.3K +7.0K (+3.9%) | 3.70M +450.5K (+13.8%) | 0.27% -0.015 pp | 0.01% +0.001 pp | USD15.40 +29.8% | 33 qtrs — |
| 51 | INTEGRATED WEALTH CONCEPTS LLC | 183.7K +183.7K (+100.0%) | 3.67M +3.7M (+100.0%) | 0.27% +0.266 pp | 0.04% +0.044 pp | USD19.99 +0.0% | 1 qtrs NEW |
| 52 | CITADEL ADVISORS LLC | 178.3K -808.7K (-81.9%) | 3.56M -14.4M (-80.2%) | 0.26% -1.312 pp | 0.00% -0.002 pp | USD19.21 +4.1% | 40 qtrs — |
| 53 | UNIVERSAL- BETEILIGUNGS- UND SERVICEGESELLSCHAFT MBH | 173.1K +57.6K (+49.9%) | 3.46M +1.3M (+64.0%) | 0.25% +0.067 pp | 0.01% +0.002 pp | USD18.82 +6.2% | 4 qtrs — |
| 54 | EXCHANGE TRADED CONCEPTS, LLC | 171.9K +2.5K (+1.5%) | 3.44M +345.1K (+11.2%) | 0.25% -0.021 pp | 0.03% 0.000 pp | USD16.51 +21.1% | 22 qtrs — |
| 55 | WINTON GROUP LTD | 169.9K +169.9K (+100.0%) | 3.40M +3.4M (+100.0%) | 0.25% +0.246 pp | 0.12% +0.117 pp | USD19.99 +0.0% | 1 qtrs NEW |
| 56 | TREXQUANT INVESTMENT LP | 163.1K +112.1K (+220.2%) | 3.26M +2.3M (+250.7%) | 0.24% +0.155 pp | 0.03% +0.020 pp | USD19.45 +2.8% | 4 qtrs — |
| 57 | TWO SIGMA ADVISERS, LP | 157.0K +64.2K (+69.2%) | 3.14M +1.4M (+85.3%) | 0.23% +0.080 pp | 0.01% +0.003 pp | USD18.25 +9.5% | 18 qtrs — |
| 58 | JPMORGAN CHASE & CO | 149.8K -69.2K (-31.6%) | 2.99M -1.0M (-25.1%) | 0.22% -0.131 pp | 0.00% 0.000 pp | USD16.31 +22.6% | 40 qtrs — |
| 59 | AMERIPRISE FINANCIAL INC | 145.0K +7.9K (+5.7%) | 2.90M +395.9K (+15.8%) | 0.21% -0.008 pp | 0.00% +0.000 pp | USD13.37 +49.5% | 37 qtrs — |
| 60 | PRUDENTIAL FINANCIAL INC | 135.7K -10.2K (-7.0%) | 2.71M +49.2K (+1.8%) | 0.20% -0.036 pp | 0.00% +0.000 pp | USD15.98 +25.1% | 37 qtrs — |
| 61 | BNP PARIBAS ASSET MANAGEMENT HOLDING S.A. | 133.9K +133.6K (+40,360.1%) | 2.68M +2.7M (+44,533.3%) | 0.19% +0.193 pp | 0.00% +0.003 pp | USD19.99 +0.0% | 3 qtrs — |
| 62 | GOTHAM ASSET MANAGEMENT, LLC | 129.5K +16.8K (+14.9%) | 2.59M +531.5K (+25.8%) | 0.19% +0.008 pp | 0.01% +0.001 pp | USD17.82 +12.2% | 40 qtrs — |
| 63 | SUSQUEHANNA PORTFOLIO STRATEGIES, LLC | 129.0K +84.7K (+191.6%) | 2.58M +1.8M (+219.4%) | 0.19% +0.116 pp | 0.04% +0.027 pp | USD20.02 -0.1% | 3 qtrs — |
| 64 | UBS ASSET MANAGEMENT AMERICAS INC | 124.0K +15.7K (+14.5%) | 2.48M +501.9K (+25.4%) | 0.18% +0.007 pp | 0.00% +0.000 pp | USD17.31 +15.5% | 40 qtrs — |
| 65 | FIRST TRUST ADVISORS LP | 118.6K +53.3K (+81.7%) | 2.37M +1.2M (+99.0%) | 0.17% +0.068 pp | 0.00% +0.001 pp | USD18.13 +10.3% | 7 qtrs — |
| 66 | SWISS NATIONAL BANK | 118.1K +2.5K (+2.2%) | 2.36M +251.1K (+11.9%) | 0.17% -0.013 pp | 0.00% +0.000 pp | USD13.83 +44.5% | 40 qtrs — |
| 67 | ALGERT GLOBAL LLC | 118.0K +106.9K (+969.4%) | 2.36M +2.2M (+1,073.1%) | 0.17% +0.153 pp | 0.04% +0.033 pp | USD19.83 +0.8% | 4 qtrs — |
| 68 | POINT72 ASSET MANAGEMENT, L.P. | 113.8K +113.8K (+100.0%) | 2.27M +2.3M (+100.0%) | 0.16% +0.165 pp | 0.00% +0.003 pp | USD19.99 +0.0% | 1 qtrs NEW |
| 69 | BRANDYWINE GLOBAL INVESTMENT MANAGEMENT, LLC | 111.7K +111.7K (+100.0%) | 2.23M +2.2M (+100.0%) | 0.16% +0.162 pp | 0.02% +0.015 pp | USD19.99 +0.0% | 1 qtrs NEW |
| 70 | MARTINGALE ASSET MANAGEMENT L P | 107.1K +27.7K (+34.9%) | 2.14M +692.6K (+47.8%) | 0.16% +0.029 pp | 0.05% +0.018 pp | USD17.57 +13.8% | 24 qtrs — |
| 71 | BRINKER CAPITAL INVESTMENTS, LLC | 105.2K +3.3K (+3.2%) | 2.10M +243.4K (+13.1%) | 0.15% -0.010 pp | 0.02% +0.001 pp | USD15.90 +25.7% | 19 qtrs — |
| 72 | HUSSMAN STRATEGIC ADVISORS, INC. | 105.0K +63.0K (+150.0%) | 2.10M +1.3M (+173.8%) | 0.15% +0.085 pp | 0.51% +0.341 pp | USD18.86 +6.0% | 21 qtrs — |
| 73 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 103.4K -11.2K (-9.8%) | 2.07M -24.5K (-1.2%) | 0.15% -0.033 pp | 0.04% -0.001 pp | USD13.94 +43.4% | 27 qtrs — |
| 74 | CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. | 93.5K -35.2K (-27.4%) | 1.87M -480.1K (-20.4%) | 0.14% -0.069 pp | 0.00% -0.003 pp | USD19.38 +3.1% | 3 qtrs — |
| 75 | FREESTONE GROVE PARTNERS LP | 91.7K -84.7K (-48.0%) | 1.83M -1.4M (-43.1%) | 0.13% -0.148 pp | 0.01% -0.011 pp | USD18.16 +10.1% | 5 qtrs — |
| 76 | VERITION FUND MANAGEMENT LLC | 91.6K -84.2K (-47.9%) | 1.83M -1.4M (-42.9%) | 0.13% -0.147 pp | 0.01% -0.006 pp | USD18.08 +10.6% | 10 qtrs — |
| 77 | O'SHAUGHNESSY ASSET MANAGEMENT, LLC | 91.3K -32.9K (-26.5%) | 1.83M -441.6K (-19.5%) | 0.13% -0.065 pp | 0.01% -0.003 pp | USD16.68 +19.8% | 31 qtrs — |
| 78 | SEI INVESTMENTS CO | 87.1K +40.4K (+86.5%) | 1.74M +888.4K (+104.3%) | 0.13% +0.052 pp | 0.00% +0.001 pp | USD19.80 +1.0% | 3 qtrs — |
| 79 | CAXTON ASSOCIATES LLP | 85.0K +57.0K (+203.3%) | 1.70M +1.2M (+232.2%) | 0.12% +0.079 pp | 0.03% +0.021 pp | USD19.39 +3.1% | 4 qtrs — |
| 80 | OLIVER LUXXE ASSETS LLC | 84.7K +84.7K (+100.0%) | 1.69M +1.7M (+100.0%) | 0.12% +0.123 pp | 0.26% +0.258 pp | USD19.99 +0.0% | 1 qtrs NEW |
| 81 | BNP PARIBAS ARBITRAGE, SNC | 84.6K -71.1K (-45.7%) | 1.69M -1.1M (-40.5%) | 0.12% -0.125 pp | 0.00% -0.001 pp | USD19.19 +4.2% | 39 qtrs — |
| 82 | QRG CAPITAL MANAGEMENT, INC. | 79.7K -678.0 (-0.8%) | 1.59M +126.3K (+8.6%) | 0.12% -0.012 pp | 0.02% +0.000 pp | USD15.56 +28.5% | 10 qtrs — |
| 83 | DENALI ADVISORS LLC | 77.2K +— (+0.0%) | 1.54M +134.3K (+9.5%) | 0.11% -0.011 pp | 0.17% +0.012 pp | USD13.98 +43.0% | 23 qtrs — |
| 84 | PRICE T ROWE ASSOCIATES INC /MD/ | 77.2K +4.7K (+6.5%) | 1.54M +220.0K (+16.6%) | 0.11% -0.004 pp | 0.00% +0.000 pp | USD15.62 +28.0% | 40 qtrs — |
| 85 | JAMES INVESTMENT RESEARCH INC | 77.2K +— (+0.0%) | 1.54M +134.3K (+9.5%) | 0.11% -0.011 pp | 0.17% +0.015 pp | USD15.37 +30.1% | 31 qtrs — |
| 86 | KLP KAPITALFORVALTNING AS | 75.5K +9.4K (+14.2%) | 1.51M +302.9K (+25.1%) | 0.11% +0.004 pp | 0.01% +0.001 pp | USD17.68 +13.1% | 5 qtrs — |
| 87 | ENGINEERS GATE MANAGER LP | 75.3K -58.1K (-43.6%) | 1.50M -929.9K (-38.2%) | 0.11% -0.103 pp | 0.02% -0.010 pp | USD18.74 +6.7% | 6 qtrs — |
| 88 | JANNEY MONTGOMERY SCOTT LLC | 75.0K -25.0K (-25.0%) | 1.50M -326.0K (-17.9%) | 0.11% -0.051 pp | 0.00% -0.001 pp | USD18.25 +9.5% | 2 qtrs — |
| 89 | EMPOWERED FUNDS, LLC | 74.6K +74.6K (+100.0%) | 1.49M +1.5M (+100.0%) | 0.11% +0.108 pp | 0.01% +0.012 pp | USD19.99 +0.0% | 1 qtrs NEW |
| 90 | SYNERGY ASSET MANAGEMENT, LLC | 74.4K -27.1K (-26.7%) | 1.49M -365.2K (-19.7%) | 0.11% -0.054 pp | 0.15% +0.088 pp | USD18.25 +9.5% | 2 qtrs — |
| 91 | LEGATO CAPITAL MANAGEMENT LLC | 71.3K +71.3K (+100.0%) | 1.42M +1.4M (+100.0%) | 0.10% +0.103 pp | 0.12% +0.123 pp | USD19.99 +0.0% | 1 qtrs NEW |
| 92 | WELLS FARGO & COMPANY/MN | 70.2K +29.3K (+71.4%) | 1.40M +656.4K (+87.8%) | 0.10% +0.037 pp | 0.00% +0.000 pp | USD17.31 +15.5% | 40 qtrs — |
| 93 | CREATIVE PLANNING | 70.1K +8.7K (+14.3%) | 1.40M +281.6K (+25.1%) | 0.10% +0.004 pp | 0.00% +0.000 pp | USD17.94 +11.4% | 11 qtrs — |
| 94 | CHASE INVESTMENT COUNSEL CORP | 70.0K +— (+0.0%) | 1.40M +122.0K (+9.6%) | 0.10% -0.010 pp | 0.39% +0.013 pp | USD16.01 +24.9% | 9 qtrs — |
| 95 | ALLIANCEBERNSTEIN L.P. | 66.6K +— (+0.0%) | 1.33M +116.0K (+9.5%) | 0.10% -0.010 pp | 0.00% +0.000 pp | USD13.31 +50.2% | 40 qtrs — |
| 96 | GREAT WEST LIFE ASSURANCE CO /CAN/ | 63.5K +11.9K (+23.1%) | 1.27M +288.0K (+29.3%) | 0.09% +0.010 pp | 0.00% +0.001 pp | USD15.94 +25.4% | 40 qtrs — |
| 97 | INSPIRE INVESTING, LLC | 62.5K +62.5K (+100.0%) | 1.25M +1.2M (+100.0%) | 0.09% +0.091 pp | 0.11% +0.112 pp | USD19.99 +0.0% | 1 qtrs NEW |
| 98 | FOX RUN MANAGEMENT, L.L.C. | 61.7K +61.7K (+100.0%) | 1.23M +1.2M (+100.0%) | 0.09% +0.089 pp | 0.19% +0.190 pp | USD19.99 +0.0% | 1 qtrs NEW |
| 99 | LSV ASSET MANAGEMENT | 58.0K +17.9K (+44.7%) | 1.16M +427.0K (+58.3%) | 0.08% +0.020 pp | 0.00% +0.001 pp | USD16.17 +23.6% | 33 qtrs — |
| 100 | CAMPBELL & CO INVESTMENT ADVISER LLC | 57.9K +45.9K (+383.3%) | 1.16M +938.3K (+429.4%) | 0.08% +0.065 pp | 0.06% +0.039 pp | USD19.36 +3.3% | 18 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 169 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Invesco Pharmaceuticals ETF PJP | 2.62% | 9.39M | 0.57% |
| 2 | ETC 6 Meridian Small Cap Equity ETF SIXS | 2.04% | 2.17M | 0.52% |
| 3 | State Street SPDR S&P Pharmaceuticals ETF XPH | 1.40% | 6.59M | 0.35% |
| 4 | Euclidean Fundamental Value ETF ECML | 1.16% | 1.59M | 0.95% |
| 5 | First Trust SMID Capital Strength ETF FSCS | 0.91% | 520.0K | 0.60% |
| 6 | Invesco S&P SmallCap Health Care ETF PSCH | 0.68% | 1.11M | 0.29% |
| 7 | First Trust Horizon Managed Volatility Small/Mid ETF HSMV | 0.68% | 234.1K | 0.80% |
| 8 | Pacer US Small Cap Cash Cows Growth Leaders ETF CAFG | 0.63% | 188.9K | 0.59% |
| 9 | VictoryShares Small Cap Free Cash Flow ETF SFLO | 0.57% | 3.64M | 0.56% |
| 10 | Distillate Small/Mid Cash Flow ETF DSMC | 0.54% | 703.1K | 0.55% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
14
Sells
0
Shares acquired
694.3K
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+694,300
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-04 | Zhen Marianne | Officer | A-Award | A | Non-statutory Stock Option | 31,500 | 22.99 | 724.2K | 31,500 | D | ↗ |
| 2026-05-04 | Small Derek A | Director | A-Award | A | Non-statutory Stock Option | 10,000 | 22.99 | 229.9K | 10,000 | D | ↗ |
| 2026-05-04 | Schlesinger Sarah J. | Director | A-Award | A | Non-statutory Stock Option | 10,000 | 22.99 | 229.9K | 10,000 | D | ↗ |
| 2026-05-04 | Raifeld Pavel | Director / Officer | A-Award | A | Non-statutory Stock Option | 312,500 | 22.99 | 7.18M | 312,500 | D | ↗ |
| 2026-05-04 | Haimovitz Jules | Director | A-Award | A | Non-statutory Stock Option | 10,000 | 22.99 | 229.9K | 10,000 | D | ↗ |
| 2026-05-04 | DiPaolo Mark | Director | A-Award | A | Non-statutory Stock Option | 10,000 | 22.99 | 229.9K | 10,000 | D | ↗ |
| 2026-05-04 | Basso Stephen | Officer | A-Award | A | Non-statutory Stock Option | 93,750 | 22.99 | 2.16M | 93,750 | D | ↗ |
| 2026-02-20 | Zhen Marianne | Officer | F-InKind | D | Common Stock | 2,460 | 23.39 | 57.5K | 45,877 | D | ↗ |
| 2026-02-20 | Raifeld Pavel | Director / Officer | F-InKind | D | Common Stock | 2,986 | 23.39 | 69.8K | 159,290 | D | ↗ |
| 2026-02-20 | Basso Stephen | Officer | F-InKind | D | Common Stock | 1,244 | 23.39 | 29.1K | 50,013 | D | ↗ |
| 2025-11-20 | Zhen Marianne | Officer | F-InKind | D | Common Stock | 992 | 21.16 | 21.0K | 48,337 | D | ↗ |
| 2025-11-20 | Basso Stephen | Officer | F-InKind | D | Common Stock | 237 | 21.16 | 5.0K | 51,257 | D | ↗ |
| 2025-11-15 | Basso Stephen | Officer | A-Award | A | Common Stock | 604 | 0.00 | — | 51,494 | D | ↗ |
| 2025-11-03 | Raifeld Pavel | 10% Owner | A-Award | A | Common Stock | 110,436 | 18.11 | 2.00M | 162,276 | D | ↗ |
| 2025-11-03 | Basso Stephen | Officer | A-Award | A | Common Stock | 27,609 | 18.11 | 500.0K | 50,890 | D | ↗ |
| 2025-08-20 | Zhen Marianne | Officer | F-InKind | D | Common Stock | 991 | 19.95 | 19.8K | 49,329 | D | ↗ |
| 2025-08-20 | Basso Stephen | Officer | F-InKind | D | Common Stock | 237 | 19.95 | 4.7K | 23,281 | D | ↗ |
| 2025-05-20 | Zhen Marianne | Officer | F-InKind | D | Common Stock | 992 | 18.78 | 18.6K | 50,320 | D | ↗ |
| 2025-05-20 | Basso Stephen | Officer | F-InKind | D | Common Stock | 237 | 18.78 | 4.5K | 23,518 | D | ↗ |
| 2025-05-19 | Small Derek A | Director | A-Award | A | Common Stock | 12,077 | 0.00 | — | 35,249 | D | ↗ |
| 2025-05-19 | Schlesinger Sarah J. | Director | A-Award | A | Common Stock | 12,077 | 0.00 | — | 130,706 | D | ↗ |
| 2025-05-19 | Haimovitz Jules | Director | A-Award | A | Non-statutory Stock Option | 10,000 | 18.63 | 186.3K | 10,000 | D | ↗ |
| 2025-05-19 | DiPaolo Mark | Director | A-Award | A | Non-statutory Stock Option | 10,000 | 18.63 | 186.3K | 10,000 | D | ↗ |
| 2025-05-15 | Raifeld Pavel | 10% Owner | A-Award | A | Common Stock | 1,860 | 0.00 | — | 51,840 | D | ↗ |
| 2025-05-15 | Basso Stephen | Officer | A-Award | A | Common Stock | 1,353 | 0.00 | — | 23,755 | D | ↗ |
| 2025-03-14 | Raifeld Pavel | 10% Owner | A-Award | A | Common Stock | 37,377 | 17.39 | 650.0K | 49,980 | D | ↗ |
| 2025-03-06 | DENNER ALEXANDER J | 10% Owner | S-Sale | D | Common Stock, par value $0.01 per share | 1,196,746 | 17.52 | 20.96M | 5,658,705 | I | ↗ |
| 2025-03-05 | DENNER ALEXANDER J | 10% Owner | S-Sale | D | Common Stock, par value $0.01 per share | 270,374 | 17.63 | 4.77M | 6,855,451 | I | ↗ |
| 2025-03-04 | DENNER ALEXANDER J | 10% Owner | S-Sale | D | Common Stock, par value $0.01 per share | 151,175 | 17.63 | 2.67M | 7,125,825 | I | ↗ |
| 2025-02-24 | Zhen Marianne | Officer | A-Award | A | Common Stock | 8,938 | 18.08 | 161.6K | 51,312 | D | ↗ |
| 2025-02-24 | Basso Stephen | Officer | A-Award | A | Non-statutory Stock Option | 100,831 | 18.08 | 1.82M | 276,730 | D | ↗ |
| 2025-02-20 | Zhen Marianne | Officer | F-InKind | D | Common Stock | 2,565 | 18.07 | 46.3K | 42,374 | D | ↗ |
| 2025-02-20 | Basso Stephen | Officer | F-InKind | D | Common Stock | 1,106 | 18.07 | 20.0K | 11,833 | D | ↗ |
| 2024-11-20 | Zhen Marianne | Officer | F-InKind | D | Common Stock | 976 | 19.15 | 18.7K | 44,939 | D | ↗ |
| 2024-11-15 | Zhen Marianne | Officer | A-Award | A | Common Stock | 300 | 0.00 | — | 45,915 | D | ↗ |
| 2024-11-15 | Basso Stephen | Officer | A-Award | A | Common Stock | 843 | 0.00 | — | 12,939 | D | ↗ |
| 2024-08-20 | Zhen Marianne | Officer | F-InKind | D | Common Stock | 975 | 18.49 | 18.0K | 45,615 | — | ↗ |
| 2024-06-17 | Srivastava Sapna | Director | A-Award | A | Non-statutory Stock Option | 10,000 | 16.16 | 161.6K | 22,500 | — | ↗ |
| 2024-06-17 | Small Derek A | Director | A-Award | A | Non-statutory Stock Option | 10,000 | 16.16 | 161.6K | 10,833 | — | ↗ |
| 2024-06-17 | Schlesinger Sarah J. | Director | A-Award | A | Non-statutory Stock Option | 10,000 | 16.16 | 161.6K | 30,000 | — | ↗ |
| 2024-06-17 | Odysseas Kostas D | Director | A-Award | A | Common Stock | 13,923 | 0.00 | — | 122,625 | — | ↗ |
| 2024-06-17 | Haimovitz Jules | Director | A-Award | A | Non-statutory Stock Option | 10,000 | 16.16 | 161.6K | 30,000 | — | ↗ |
| 2024-06-17 | DiPaolo Mark | Director | A-Award | A | Non-statutory Stock Option | 10,000 | 16.16 | 161.6K | 30,000 | — | ↗ |
| 2024-05-20 | Zhen Marianne | Officer | F-InKind | D | Common Stock | 976 | 16.13 | 15.7K | 46,590 | — | ↗ |
| 2024-05-20 | Ronsheim Matthew | Officer | F-InKind | D | Common Stock | 268 | 16.13 | 4.3K | 40,510 | — | ↗ |
| 2024-04-29 | Small Derek A | Director | — | D | Stock Options | 833 | 0.00 | — | 0 | — | ↗ |
| 2024-03-05 | Zhen Marianne | Officer | A-Award | A | Non-statutory Stock Option | 23,022 | 14.88 | 342.6K | 63,022 | — | ↗ |
| 2024-03-05 | Ronsheim Matthew | Officer | A-Award | A | Non-statutory Stock Option | 27,338 | 14.88 | 406.8K | 120,438 | — | ↗ |
| 2024-03-05 | Raifeld Pavel | Officer | A-Award | A | Non-statutory Stock Option | 150,000 | 20.00 | 3.00M | 825,000 | — | ↗ |
| 2024-03-05 | Basso Stephen | Officer | A-Award | A | Non-statutory Stock Option | 25,899 | 14.88 | 385.4K | 175,899 | — | ↗ |
| 2024-02-20 | Zhen Marianne | Officer | F-InKind | D | Common Stock | 2,862 | 15.80 | 45.2K | 36,814 | — | ↗ |
| 2024-02-20 | Ronsheim Matthew | Officer | F-InKind | D | Common Stock | 807 | 15.80 | 12.8K | 28,010 | — | ↗ |
| 2024-01-18 | Ronsheim Matthew | Officer | A-Award | A | Nonqualified Stock Option | 60,000 | 16.05 | 963.0K | 93,100 | — | ↗ |
| 2024-01-01 | Ronsheim Matthew | Officer | — | D | Common Stock | 0 | 0.00 | — | 12,945 | — | ↗ |
| 2023-11-20 | Zhen Marianne | Officer | F-InKind | D | Common Stock | 784 | 13.62 | 10.7K | 39,676 | — | ↗ |
| 2023-11-15 | Zhen Marianne | Officer | S-Sale | D | Common Stock | 5,405 | 13.97 | 75.5K | 40,158 | — | ↗ |
| 2023-08-31 | Basso Stephen | Officer | A-Award | A | Nonqualified Stock Option | 150,000 | 12.75 | 1.91M | 150,000 | — | ↗ |
| 2023-08-21 | Basso Stephen | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-08-18 | Zhen Marianne | Officer | F-InKind | D | Common Stock | 785 | 13.64 | 10.7K | 51,152 | — | ↗ |
| 2023-07-31 | Koziel Margaret | Officer | A-Award | A | Nonqualified Stock Option | 60,000 | 13.55 | 813.0K | 60,000 | — | ↗ |
| 2023-06-15 | DENNER ALEXANDER J | 10% Owner | P-Purchase | A | Common Stock, par value $0.01 per share | 62,000 | 13.13 | 814.2K | 7,277,000 | — | ↗ |
| 2023-06-06 | DENNER ALEXANDER J | 10% Owner | P-Purchase | A | Common Stock, par value $0.01 per share | 8,000 | 13.05 | 104.4K | 7,215,000 | — | ↗ |
| 2023-06-05 | DENNER ALEXANDER J | 10% Owner | P-Purchase | A | Common Stock, par value $0.01 per share | 7,000 | 13.04 | 91.3K | 7,207,000 | — | ↗ |
| 2023-05-30 | DENNER ALEXANDER J | 10% Owner | P-Purchase | A | Common Stock, par value $0.01 per share | 120,000 | 13.01 | 1.56M | 7,200,000 | — | ↗ |
| 2023-05-26 | DENNER ALEXANDER J | 10% Owner | P-Purchase | A | Common Stock, par value $0.01 per share | 30,000 | 13.12 | 393.7K | 7,080,000 | — | ↗ |
| 2023-05-25 | DENNER ALEXANDER J | 10% Owner | P-Purchase | A | Common Stock, par value $0.01 per share | 50,000 | 13.09 | 654.3K | 7,050,000 | — | ↗ |
| 2023-05-22 | Srivastava Sapna | Director | A-Award | A | Common Stock | 16,495 | 0.00 | — | 30,173 | — | ↗ |
| 2023-05-22 | Schlesinger Sarah J. | Director | A-Award | A | Common Stock | 16,495 | 0.00 | — | 104,706 | — | ↗ |
| 2023-05-22 | Odysseas Kostas D | Director | A-Award | A | Common Stock | 16,495 | 0.00 | — | 108,702 | — | ↗ |
| 2023-05-22 | Haimovitz Jules | Director | A-Award | A | Common Stock | 16,495 | 0.00 | — | 116,906 | — | ↗ |
| 2023-05-22 | DiPaolo Mark | Director | A-Award | A | Common Stock | 16,495 | 0.00 | — | 104,706 | — | ↗ |
| 2023-05-22 | Birx Deborah | Director | A-Award | A | Common Stock | 16,495 | 0.00 | — | 58,984 | — | ↗ |
| 2023-05-19 | Zhen Marianne | Officer | F-InKind | D | Common Stock | 784 | 13.47 | 10.6K | 51,937 | — | ↗ |
| 2023-05-19 | DENNER ALEXANDER J | 10% Owner | P-Purchase | A | Common Stock, par value $0.01 per share | 36,000 | 13.48 | 485.1K | 7,000,000 | — | ↗ |
| 2023-05-18 | DENNER ALEXANDER J | 10% Owner | P-Purchase | A | Common Stock, par value $0.01 per share | 10,000 | 13.05 | 130.5K | 6,964,000 | — | ↗ |
| 2023-05-17 | DENNER ALEXANDER J | 10% Owner | P-Purchase | A | Common Stock, par value $0.01 per share | 50,000 | 13.07 | 653.7K | 6,954,000 | — | ↗ |
| 2023-05-15 | Zhen Marianne | Officer | A-Award | A | Common Stock | 1,576 | 0.00 | — | 52,721 | — | ↗ |
| 2023-05-11 | DENNER ALEXANDER J | 10% Owner | P-Purchase | A | Common Stock, par value $0.01 per share | 290,000 | 12.34 | 3.58M | 6,904,000 | — | ↗ |
| 2023-05-09 | DENNER ALEXANDER J | 10% Owner | — | I | Common Stock, par value $0.01 per share | 0 | 0.00 | — | 6,614,000 | — | ↗ |
| 2023-04-13 | Zhen Marianne | Officer | A-Award | A | Common Stock | 14,344 | 0.00 | — | 51,145 | — | ↗ |
| 2023-03-10 | Raifeld Pavel | Officer | P-Purchase | A | Common Stock | 3,000 | 10.87 | 32.6K | 9,799 | — | ↗ |
| 2023-02-17 | Zhen Marianne | Officer | F-InKind | D | Common Stock | 1,852 | 12.42 | 23.0K | 36,801 | — | ↗ |
| 2023-01-01 | Srivastava Sapna | Director | — | D | Stock Options | 2,500 | 0.00 | — | — | — | ↗ |
| 2022-11-18 | Zhen Marianne | Officer | F-InKind | D | Common Stock | 828 | 13.55 | 11.2K | 38,653 | — | ↗ |
| 2022-11-15 | Zhen Marianne | Officer | A-Award | A | Common Stock | 433 | 0.00 | — | 39,481 | — | ↗ |
| 2022-08-22 | Edwards Larry G. | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-08-19 | Zhen Marianne | Officer | F-InKind | D | Common Stock | 830 | 14.12 | 11.7K | 39,048 | — | ↗ |
| 2022-05-20 | Zhen Marianne | Officer | A-Award | A | Common Stock | 1,834 | 0.00 | — | 40,706 | — | ↗ |
| 2022-04-29 | Raifeld Pavel | Officer | A-Award | A | Nonstatutory Stock Option | 150,000 | 0.00 | — | 500,000 | — | ↗ |
| 2022-04-25 | Schlesinger Sarah J. | Director | A-Award | A | Common Stock | 12,647 | 0.00 | — | 88,211 | — | ↗ |
| 2022-04-25 | Odysseas Kostas D | Director | A-Award | A | Non-statutory Stock Option | 10,000 | 10,000.00 | 100.00M | 0 | — | ↗ |
| 2022-04-25 | Haimovitz Jules | Director | A-Award | A | Non-statutory Stock Option | 10,000 | 0.00 | — | 10,000 | — | ↗ |
| 2022-04-25 | DiPaolo Mark | Director | A-Award | A | Non-statutory Stock Option | 10,000 | 0.00 | — | 10,000 | — | ↗ |
| 2022-04-25 | Birx Deborah | Director | A-Award | A | Common Stock | 12,647 | 0.00 | — | 42,489 | — | ↗ |
| 2022-04-25 | Bickerstaff George | Director | A-Award | A | Common Stock | 12,647 | 0.00 | — | 137,207 | — | ↗ |
| 2022-03-01 | Zhen Marianne | Officer | A-Award | A | Common Stock | 6,691 | 0.00 | — | 38,872 | — | ↗ |
| 2022-02-18 | Zhen Marianne | Officer | F-InKind | D | Common Stock | 2,277 | 19.99 | 45.5K | 32,181 | — | ↗ |
| 2021-11-19 | Zhen Marianne | Officer | F-InKind | D | Common Stock | 758 | 17.05 | 12.9K | 34,458 | — | ↗ |
| 2021-08-20 | Zhen Marianne | Officer | S-Sale | D | Common Stock | 1,129 | 15.89 | 17.9K | 35,364 | — | ↗ |
| 2021-08-19 | Zhen Marianne | Officer | S-Sale | D | Common Stock | 2,802 | 16.02 | 44.9K | 36,493 | — | ↗ |
| 2021-05-24 | Bickerstaff George | Director | P-Purchase | A | Common Stock | 10,000 | 13.46 | 134.6K | 124,560 | — | ↗ |
| 2021-05-21 | Raifeld Pavel | Officer | A-Award | A | Nonstatutory Stock Option | 100,000 | 0.00 | — | 350,000 | — | ↗ |
| 2021-05-21 | Bickerstaff George | Director | P-Purchase | A | Common Stock | 10,000 | 12.97 | 129.7K | 114,560 | — | ↗ |
| 2021-05-20 | Zhen Marianne | Officer | F-InKind | D | Common Stock | 759 | 13.32 | 10.1K | 39,295 | — | ↗ |
| 2021-05-20 | Raifeld Pavel | Officer | — | D | Nonstatutory Stock Option | 250,000 | 14.10 | 3.53M | 0 | — | ↗ |
| 2021-05-20 | GLAXOSMITHKLINE PLC | 10% Owner | S-Sale | D | Common Stock | 32,005,260 | 12.25 | 392.06M | 0 | — | ↗ |
| 2021-05-14 | Schlesinger Sarah J. | Director | A-Award | A | Common Stock | 17,482 | 0.00 | — | 75,564 | — | ↗ |
| 2021-05-14 | Odysseas Kostas D | Director | A-Award | A | Common Stock | 17,482 | 0.00 | — | 79,560 | — | ↗ |
| 2021-05-14 | Haimovitz Jules | Director | A-Award | A | Common Stock | 17,482 | 0.00 | — | 87,764 | — | ↗ |
| 2021-05-14 | DiPaolo Mark | Director | A-Award | A | Common Stock | 17,482 | 0.00 | — | 75,564 | — | ↗ |
| 2021-05-14 | Birx Deborah | Director | A-Award | A | Common Stock | 17,482 | 0.00 | — | 29,842 | — | ↗ |
| 2021-05-14 | Bickerstaff George | Director | A-Award | A | Common Stock | 17,482 | 0.00 | — | 104,560 | — | ↗ |
| 2021-03-29 | Zhen Marianne | Officer | A-Award | A | Common Stock | 10,305 | 0.00 | — | 38,399 | — | ↗ |
| 2021-03-29 | Birx Deborah | Director | A-Award | A | Common Stock | 1,612 | 0.00 | — | 12,360 | — | ↗ |
| 2021-03-22 | Birx Deborah | Director | A-Award | A | Restricted Stock Units | 10,748 | 0.00 | — | 10,748 | — | ↗ |
| 2021-03-09 | Birx Deborah | Director | — | D | No securities beneficially owned | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-02-19 | Zhen Marianne | Officer | F-InKind | D | Common Stock | 2,108 | 11.74 | 24.7K | 28,094 | — | ↗ |
| 2020-11-20 | Zhen Marianne | Officer | F-InKind | D | Common Stock | 798 | 10.95 | 8.7K | 30,202 | — | ↗ |
| 2020-08-20 | Zhen Marianne | Officer | F-InKind | D | Common Stock | 797 | 13.19 | 10.5K | 30,243 | — | ↗ |
| 2020-05-20 | Zhen Marianne | Officer | F-InKind | D | Common Stock | 866 | 14.10 | 12.2K | 31,040 | — | ↗ |
| 2020-05-20 | HULME GEOFFREY | Officer | F-InKind | D | Common Stock | 339 | 14.10 | 4.8K | 46,251 | — | ↗ |
| 2020-04-24 | Schlesinger Sarah J. | Director | A-Award | A | Common Stock | 16,917 | 0.00 | — | 58,082 | — | ↗ |
| 2020-04-24 | Odysseas Kostas D | Director | A-Award | A | Common Stock | 16,917 | 0.00 | — | 62,078 | — | ↗ |
| 2020-04-24 | Haimovitz Jules | Director | A-Award | A | Common Stock | 16,917 | 0.00 | — | 70,282 | — | ↗ |
| 2020-04-24 | DiPaolo Mark | Director | A-Award | A | Common Stock | 16,917 | 0.00 | — | 58,082 | — | ↗ |
| 2020-04-24 | Bickerstaff George | Director | A-Award | A | Common Stock | 16,917 | 0.00 | — | 87,078 | — | ↗ |
| 2020-02-24 | Zhen Marianne | Officer | S-Sale | D | Common Stock | 2,954 | 14.78 | 43.7K | 21,913 | — | ↗ |
| 2020-02-20 | Zhen Marianne | Officer | F-InKind | D | Common Stock | 2,073 | 15.10 | 31.3K | 24,867 | — | ↗ |
| 2020-02-20 | HULME GEOFFREY | Officer | F-InKind | D | Common Stock | 1,549 | 15.10 | 23.4K | 29,735 | — | ↗ |
| 2020-02-03 | Zhen Marianne | Officer | A-Award | A | Common Stock | 8,741 | 0.00 | — | 30,654 | — | ↗ |
| 2020-02-03 | HULME GEOFFREY | Officer | A-Award | A | Common Stock | 15,734 | 0.00 | — | 45,469 | — | ↗ |
| 2019-11-20 | Zhen Marianne | Officer | F-InKind | D | Common Stock | 602 | 12.59 | 7.6K | 26,940 | — | ↗ |
| 2019-09-04 | HULME GEOFFREY | Officer | A-Award | A | Common Stock | 3,000 | 10.89 | 32.7K | 31,000 | — | ↗ |
| 2019-08-20 | Zhen Marianne | Officer | F-InKind | D | Common Stock | 600 | 11.50 | 6.9K | 27,542 | — | ↗ |
| 2019-05-20 | Zhen Marianne | Officer | F-InKind | D | Common Stock | 601 | 14.21 | 8.5K | 28,142 | — | ↗ |
| 2019-04-24 | Schlesinger Sarah J. | Director | A-Award | A | Common Stock | 16,399 | 0.00 | — | 41,165 | — | ↗ |
| 2019-04-24 | Odysseas Kostas D | Director | A-Award | A | Common Stock | 16,399 | 0.00 | — | 45,161 | — | ↗ |
| 2019-04-24 | Haimovitz Jules | Director | A-Award | A | Common Stock | 16,399 | 0.00 | — | 53,365 | — | ↗ |
| 2019-04-24 | DiPaolo Mark | Director | A-Award | A | Common Stock | 16,399 | 0.00 | — | 41,165 | — | ↗ |
| 2019-04-24 | Bickerstaff George | Director | A-Award | A | Common Stock | 16,399 | 0.00 | — | 70,161 | — | ↗ |
| 2019-03-01 | Zhen Marianne | Officer | A-Award | A | Common Stock | 8,154 | 0.00 | — | 26,818 | — | ↗ |
| 2019-03-01 | HULME GEOFFREY | Officer | A-Award | A | Common Stock | 14,677 | 0.00 | — | 27,584 | — | ↗ |
| 2019-02-27 | Bickerstaff George | Director | P-Purchase | A | Common Stock | 15,000 | 15.90 | 238.5K | 53,762 | — | ↗ |
| 2019-02-26 | Zhen Marianne | Officer | S-Sale | D | Common Stock | 5,617 | 16.00 | 89.9K | 18,664 | — | ↗ |
| 2019-02-21 | Bickerstaff George | Director | P-Purchase | A | Common Stock | 10,000 | 14.90 | 149.0K | 38,762 | — | ↗ |
| 2019-02-20 | Zhen Marianne | Officer | F-InKind | D | Common Stock | 1,353 | 14.67 | 19.8K | 24,281 | — | ↗ |
| 2019-02-19 | HULME GEOFFREY | Officer | F-InKind | D | Common Stock | 3,093 | 14.53 | 44.9K | 12,907 | — | ↗ |
| 2019-02-15 | HULME GEOFFREY | Officer | P-Purchase | A | Common Stock | 7,000 | 14.80 | 103.6K | 7,000 | — | ↗ |
| 2018-11-20 | Zhen Marianne | Officer | F-InKind | D | Common Stock | 540 | 16.43 | 8.9K | 25,634 | — | ↗ |
| 2018-09-07 | Zhen Marianne | Officer | A-Award | A | Common Stock | 1,779 | 0.00 | — | 23,347 | — | ↗ |
| 2018-08-21 | Witek Theodore J. Jr. | Officer | S-Sale | D | Common Stock | 8,504 | 14.12 | 120.1K | 247,767 | — | ↗ |
| 2018-08-21 | ABERCROMBIE GEORGE B | Officer | S-Sale | D | Common Stock | 8,000 | 14.11 | 112.8K | 285,479 | — | ↗ |
| 2018-08-20 | Zhen Marianne | Officer | F-InKind | D | Common Stock | 536 | 14.08 | 7.5K | 23,568 | — | ↗ |
| 2018-08-20 | Witek Theodore J. Jr. | Officer | F-InKind | D | Common Stock | 3,089 | 14.08 | 43.5K | 256,271 | — | ↗ |
| 2018-08-20 | ABERCROMBIE GEORGE B | Officer | F-InKind | D | Common Stock | 5,680 | 14.08 | 80.0K | 293,479 | — | ↗ |
| 2018-08-03 | Zhen Marianne | Officer | — | D | Common Stock | 0 | 0.00 | — | 24,104 | — | ↗ |
| 2018-05-21 | dEsparbes Eric | Officer | S-Sale | D | Common Stock | 5,808 | 14.40 | 83.6K | 373,081 | — | ↗ |
| 2018-05-21 | HULME GEOFFREY | Officer | — | I | Common Stock | 0 | 0.00 | — | 3,500 | — | ↗ |
| 2018-05-21 | ABERCROMBIE GEORGE B | Officer | S-Sale | D | Common Stock | 8,000 | 14.40 | 115.2K | 299,159 | — | ↗ |
| 2018-05-20 | dEsparbes Eric | Officer | F-InKind | D | Common Stock | 7,901 | 14.59 | 115.3K | 376,965 | — | ↗ |
| 2018-05-20 | Witek Theodore J. Jr. | Officer | F-InKind | D | Common Stock | 3,089 | 14.59 | 45.1K | 259,360 | — | ↗ |
| 2018-05-20 | ABERCROMBIE GEORGE B | Officer | F-InKind | D | Common Stock | 4,682 | 14.59 | 68.3K | 305,235 | — | ↗ |
| 2018-04-24 | Schlesinger Sarah J. | Director | A-Award | A | Common Stock | 14,249 | 0.00 | — | 24,766 | — | ↗ |
| 2018-04-24 | Odysseas Kostas D | Director | A-Award | A | Common Stock | 14,249 | 0.00 | — | 28,762 | — | ↗ |
| 2018-04-24 | Haimovitz Jules | Director | A-Award | A | Common Stock | 14,249 | 0.00 | — | 36,966 | — | ↗ |
| 2018-04-24 | DiPaolo Mark | Director | A-Award | A | Common Stock | 14,249 | 0.00 | — | 24,766 | — | ↗ |
| 2018-04-24 | Bickerstaff George | Director | A-Award | A | Common Stock | 14,249 | 0.00 | — | 28,762 | — | ↗ |
| 2018-03-02 | dEsparbes Eric | Officer | A-Award | A | Common Stock | 93,056 | 0.00 | — | 384,866 | — | ↗ |
| 2018-03-02 | Witek Theodore J. Jr. | Officer | A-Award | A | Common Stock | 74,444 | 0.00 | — | 262,017 | — | ↗ |
| 2018-03-02 | ABERCROMBIE GEORGE B | Officer | A-Award | A | Common Stock | 74,444 | 0.00 | — | 309,917 | — | ↗ |
| 2018-02-21 | dEsparbes Eric | Officer | S-Sale | D | Common Stock | 5,378 | 16.52 | 88.8K | 291,810 | — | ↗ |
| 2018-02-21 | Witek Theodore J. Jr. | Officer | S-Sale | D | Common Stock | 9,890 | 16.60 | 164.1K | 187,573 | — | ↗ |
| 2018-02-21 | ABERCROMBIE GEORGE B | Officer | S-Sale | D | Common Stock | 8,000 | 16.51 | 132.1K | 235,473 | — | ↗ |
| 2018-02-20 | dEsparbes Eric | Officer | F-InKind | D | Common Stock | 24,876 | 16.44 | 409.0K | 297,188 | — | ↗ |
| 2018-02-20 | Witek Theodore J. Jr. | Officer | F-InKind | D | Common Stock | 16,700 | 16.44 | 274.5K | 197,463 | — | ↗ |
| 2018-02-20 | ABERCROMBIE GEORGE B | Officer | F-InKind | D | Common Stock | 15,500 | 16.44 | 254.8K | 243,473 | — | ↗ |
| 2018-02-12 | Schlesinger Sarah J. | Director | A-Award | A | Common Stock | 10,517 | 0.00 | — | 10,517 | — | ↗ |
| 2018-02-12 | Haimovitz Jules | Director | A-Award | A | Common Stock | 10,517 | 0.00 | — | 22,717 | — | ↗ |
| 2018-02-12 | DiPaolo Mark | Director | A-Award | A | Common Stock | 10,517 | 0.00 | — | 10,517 | — | ↗ |
| 2017-12-19 | Kostas Odysseas D | Director | A-Award | A | Common Stock | 14,513 | 0.00 | — | 14,513 | — | ↗ |
| 2017-12-19 | Bickerstaff George | Director | A-Award | A | Common Stock | 14,513 | 0.00 | — | 14,513 | — | ↗ |
| 2017-12-04 | Aguiar Michael W | Director / Officer | S-Sale | D | Common Stock | 12,022 | 13.13 | 157.8K | 980,907 | — | ↗ |
| 2017-11-21 | dEsparbes Eric | Officer | S-Sale | D | Common Stock | 13,460 | 13.31 | 179.2K | 321,742 | — | ↗ |
| 2017-11-21 | Witek Theodore J. Jr. | Officer | S-Sale | D | Common Stock | 13,000 | 13.29 | 172.8K | 213,800 | — | ↗ |
| 2017-11-21 | ABERCROMBIE GEORGE B | Officer | S-Sale | D | Common Stock | 5,215 | 13.26 | 69.1K | 258,651 | — | ↗ |
| 2017-11-20 | dEsparbes Eric | Officer | F-InKind | D | Common Stock | 6,141 | 13.17 | 80.9K | 337,027 | — | ↗ |
| 2017-11-20 | Witek Theodore J. Jr. | Officer | F-InKind | D | Common Stock | 14,757 | 13.17 | 194.3K | 226,800 | — | ↗ |
| 2017-11-20 | Faerm Michael E. | Officer | F-InKind | D | Common Stock | 4,470 | 13.17 | 58.9K | 279,422 | — | ↗ |
| 2017-11-20 | Aguiar Michael W | Director / Officer | F-InKind | D | Common Stock | 43,038 | 13.17 | 566.8K | 992,929 | — | ↗ |
| 2017-11-20 | ABERCROMBIE GEORGE B | Officer | F-InKind | D | Common Stock | 3,358 | 13.17 | 44.2K | 263,866 | — | ↗ |
| 2017-08-21 | dEsparbes Eric | Officer | S-Sale | D | Common Stock | 1,825 | 12.20 | 22.3K | 343,168 | — | ↗ |
| 2017-08-20 | dEsparbes Eric | Officer | F-InKind | D | Common Stock | 5,770 | 12.28 | 70.9K | 344,993 | — | ↗ |
| 2017-08-20 | Witek Theodore J. Jr. | Officer | F-InKind | D | Common Stock | 2,596 | 12.28 | 31.9K | 241,557 | — | ↗ |
| 2017-08-20 | Faerm Michael E. | Officer | F-InKind | D | Common Stock | 3,179 | 12.28 | 39.0K | 283,892 | — | ↗ |
| 2017-08-20 | Aguiar Michael W | Director / Officer | F-InKind | D | Common Stock | 12,917 | 12.28 | 158.6K | 1,035,967 | — | ↗ |
| 2017-08-20 | ABERCROMBIE GEORGE B | Officer | F-InKind | D | Common Stock | 2,886 | 12.28 | 35.4K | 267,224 | — | ↗ |
| 2017-05-22 | dEsparbes Eric | Officer | S-Sale | D | Common Stock | 1,825 | 11.85 | 21.6K | 350,763 | — | ↗ |
| 2017-05-22 | Witek Theodore J. Jr. | Officer | S-Sale | D | Common Stock | 7,815 | 12.01 | 93.9K | 244,153 | — | ↗ |
| 2017-05-20 | dEsparbes Eric | Officer | F-InKind | D | Common Stock | 4,208 | 11.86 | 49.9K | 352,588 | — | ↗ |
| 2017-05-20 | Witek Theodore J. Jr. | Officer | F-InKind | D | Common Stock | 2,590 | 11.86 | 30.7K | 251,968 | — | ↗ |
Executive team
Top executives
EBIT / Employee
2.71M
Shares Outstanding
64.34M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Pavel Raifeld Chief Executive Officer | 600.0K | 378.0K | 2.65M | 1.75M | — | 23.3K | 5.40M | 81.46% | ↗ |
| 2 | 2025 | Stephen Basso Chief Financial Officer and President of IST | 475.0K | 223.5K | 691.1K | 765.3K | — | 18.3K | 2.17M | 67.08% | ↗ |
| 3 | 2025 | Marianne Zhen Chief Accounting Officer | 420.0K | 245.4K | 161.6K | 230.0K | — | 25.8K | 1.08M | 36.16% | ↗ |
| 4 | 2024 | Pavel Raifeld Chief Executive Officer | 503.3K | 414.7K | — | 1.78M | — | 23.0K | 2.72M | 65.36% | ↗ |
| 5 | 2024 | Matthew Ronsheim Former President, IST | 289.7K | — | 190.0K | 591.5K | — | 11.6K | 1.08M | 72.18% | ↗ |
| 6 | 2024 | Stephen Basso Chief Financial Officer and Interim President of IST | 454.5K | 187.3K | 180.0K | 166.3K | — | 21.7K | 1.01M | 34.30% | ↗ |
| 7 | 2024 | Stephen Basso Chief Financial Officer and President of IST | 454.5K | 187.3K | 180.0K | 166.3K | — | 21.7K | 1.01M | 34.30% | ↗ |
| 8 | 2024 | Marianne Zhen Chief Accounting Officer | 404.0K | 230.0K | 160.0K | 147.9K | — | 25.5K | 967.3K | 31.82% | ↗ |
| 9 | 2023 | Larry Edwards President | 145.8K | — | — | — | — | 1.28M | 1.43M | 0.00% | ↗ |
| 10 | 2023 | Stephen Basso Chief Financial Officer and President of IST | 164.1K | 163.4K | — | 845.6K | — | 9.0K | 1.18M | 71.54% | ↗ |
| 11 | 2023 | Stephen Basso Chief Financial Officer | 164.1K | 163.4K | — | 845.6K | — | 9.0K | 1.18M | 71.54% | ↗ |
| 12 | 2023 | Stephen Basso Chief Financial Officer and Interim President of IST | 164.1K | 163.4K | — | 845.6K | — | 9.0K | 1.18M | 71.54% | ↗ |
| 13 | 2023 | Margaret Koziel, M.D. Chief Medical Officer | 187.5K | 300.0K | — | 356.4K | — | 123.8K | 967.7K | 36.83% | ↗ |
| 14 | 2023 | Marianne Zhen Chief Accounting Officer | 400.0K | 220.6K | 175.0K | 104.2K | — | 24.5K | 924.2K | 30.21% | ↗ |
| 15 | 2023 | Pavel Raifeld Chief Executive Officer | 485.0K | 361.6K | — | — | — | 22.0K | 868.6K | 0.00% | ↗ |
| 16 | 2022 | Pavel Raifeld Chief Executive Officer | 440.0K | 294.3K | — | 1.04M | — | 20.3K | 1.80M | 58.05% | ↗ |
| 17 | 2022 | Marianne Zhen Chief Accounting Officer | 329.2K | 178.5K | 125.0K | 115.9K | — | 22.5K | 771.1K | 31.24% | ↗ |
| 18 | 2022 | Larry Edwards Former President and Chief Executive Officer of La Jolla Pharmaceutical Company | 209.6K | 349.8K | — | — | — | — | 559.4K | 0.00% | ↗ |
| 19 | 2022 | Larry Edwards President | 209.6K | 349.8K | — | — | — | — | 559.4K | 0.00% | ↗ |
| 20 | 2021 | Pavel Raifeld Chief Executive Officer | 391.5K | 235.0K | — | 580.3K | — | 64.9K | 1.27M | 45.65% | ↗ |
| 21 | 2021 | Marianne Zhen Chief Accounting Officer | 296.2K | 144.5K | 125.0K | 27.1K | — | 21.5K | 614.3K | 24.76% | ↗ |
| 22 | 2020 | Pavel Raifeld Chief Executive Officer | 222.0K | 124.0K | — | 1.57M | — | 19.0K | 1.94M | 80.76% | ↗ |
| 23 | 2020 | Geoffrey L. Hulme Interim Principal Executive Officer | 120.3K | — | 225.0K | — | — | 370.9K | 716.2K | 31.41% | ↗ |
| 24 | 2020 | Marianne Zhen Chief Accounting Officer | 284.6K | 128.1K | 125.0K | — | — | 21.2K | 558.9K | 22.37% | ↗ |
| 25 | 2019 | Geoffrey L. Hulme Interim Principal Executive Officer | 300.0K | 180.0K | 355.8K | — | — | 20.7K | 856.4K | 41.54% | ↗ |
| 26 | 2019 | Marianne Zhen Chief Accounting Officer | 275.0K | 123.8K | 125.0K | — | 7.5K | 20.7K | 551.9K | 22.65% | ↗ |
| 27 | 2018 | Michael W. Aguiar Former President and Chief Executive Officer | 76.4K | — | 903.5K | — | — | 2.73M | 3.71M | 24.38% | ↗ |
| 28 | 2018 | Eric d'Esparbes Former Senior Vice President and Chief Financial Officer | 280.2K | — | 1.18M | — | — | 1.37M | 2.83M | 41.57% | ↗ |
| 29 | 2018 | George B. Abercrombie Former Senior Vice President and Chief Commercial Officer | 325.2K | — | 934.8K | — | — | 624.4K | 1.88M | 49.61% | ↗ |
| 30 | 2018 | Theodore J. Witek, Jr. Former Senior Vice President and Chief Scientific Officer Clinical and Medical Affairs | 324.2K | — | 920.4K | — | — | 628.8K | 1.87M | 49.13% | ↗ |
| 31 | 2018 | Marianne Zhen Chief Accounting Officer | 239.6K | 77.5K | 124.9K | — | 15.0K | 20.3K | 477.4K | 26.17% | ↗ |
| 32 | 2018 | Geoffrey L. Hulme Interim Principal Executive Officer | 184.4K | 110.3K | — | — | — | 7.5K | 302.2K | 0.00% | ↗ |
| 33 | 2017 | Michael W. Aguiar Former President and Chief Executive Officer | 772.8K | 250.0K | 3.13M | — | — | 20.0K | 4.18M | 75.03% | ↗ |
| 34 | 2017 | Michael W. Aguiar President and Chief Executive Officer | 772.8K | 250.0K | 3.13M | — | — | 20.0K | 4.18M | 75.03% | ↗ |
| 35 | 2017 | Eric d'Esparbes Former Senior Vice President and Chief Financial Officer | 441.5K | — | 1.25M | — | 220.8K | 12.0K | 1.93M | 65.02% | ↗ |
| 36 | 2017 | Eric d'Esparbes Senior Vice President and Chief Financial Officer | 441.5K | — | 1.25M | — | 220.8K | 12.0K | 1.93M | 65.02% | ↗ |
| 37 | 2017 | Michael E. Faerm Senior Vice President and Chief Business Officer | 436.4K | 100.0K | 1.25M | — | — | 20.0K | 1.81M | 69.26% | ↗ |
| 38 | 2017 | Theodore J. Witek, Jr. Senior Vice President and Chief Scientific Officer Clinical and Medical Affairs | 435.3K | — | 999.7K | — | 217.7K | 32.0K | 1.68M | 59.34% | ↗ |
| 39 | 2017 | Theodore J. Witek, Jr. Former Senior Vice President and Chief Scientific Officer Clinical and Medical Affairs | 435.3K | — | 999.7K | — | 217.7K | 32.0K | 1.68M | 59.34% | ↗ |
| 40 | 2017 | George B. Abercrombie Senior Vice President and Chief Commercial Officer | 436.7K | — | 1.00M | — | 218.3K | 20.0K | 1.68M | 59.77% | ↗ |
| 41 | 2017 | George B. Abercrombie Former Senior Vice President and Chief Commercial Officer | 436.7K | — | 1.00M | — | 218.3K | 20.0K | 1.68M | 59.77% | ↗ |
| 42 | 2016 | Michael W. Aguiar President and Chief Executive Officer | 746.7K | — | 2.16M | — | 672.0K | 19.7K | 3.60M | 60.02% | ↗ |
| 43 | 2016 | Michael W. Aguiar Former President and Chief Executive Officer | 746.7K | — | 2.16M | — | 672.0K | 19.7K | 3.60M | 60.02% | ↗ |
| 44 | 2016 | Eric d'Esparbes Senior Vice President and Chief Financial Officer | 422.9K | — | 863.7K | — | 253.8K | 9.6K | 1.55M | 55.72% | ↗ |
| 45 | 2016 | Eric d'Esparbes Former Senior Vice President and Chief Financial Officer | 422.9K | — | 863.7K | — | 253.8K | 9.6K | 1.55M | 55.72% | ↗ |
| 46 | 2016 | George B. Abercrombie Senior Vice President and Chief Commercial Officer | 421.9K | 21.1K | 690.9K | — | 253.2K | 12.0K | 1.40M | 49.38% | ↗ |
| 47 | 2016 | George B. Abercrombie Former Senior Vice President and Chief Commercial Officer | 421.9K | 21.1K | 690.9K | — | 253.2K | 12.0K | 1.40M | 49.38% | ↗ |
| 48 | 2016 | Theodore J. Witek, Jr. Former Senior Vice President and Chief Scientific Officer Clinical and Medical Affairs | 420.6K | — | 681.9K | — | 252.4K | 23.7K | 1.38M | 49.46% | ↗ |
| 49 | 2016 | Theodore J. Witek, Jr. Senior Vice President and Chief Scientific Officer Clinical and Medical Affairs | 420.6K | — | 681.9K | — | 252.4K | 23.7K | 1.38M | 49.46% | ↗ |
| 50 | 2016 | Michael E. Faerm Senior Vice President and Chief Business Officer | 422.4K | — | 500.9K | — | 253.4K | 193.2K | 1.37M | 36.57% | ↗ |
| 51 | 2015 | Michael W. Aguiar President and Chief Executive Officer | 721.4K | — | 2.31M | — | 516.2K | 9.0K | 3.56M | 64.99% | ↗ |
| 52 | 2015 | Michael E. Faerm Senior Vice President and Chief Business Officer | 199.6K | 75.0K | 1.64M | — | 114.3K | 33.0K | 2.07M | 79.58% | ↗ |
| 53 | 2015 | George B. Abercrombie Senior Vice President and Chief Commercial Officer | 408.2K | — | 938.9K | — | 194.5K | 12.0K | 1.55M | 60.44% | ↗ |
| 54 | 2015 | Theodore J. Witek, Jr. Senior Vice President and Chief Scientific Officer Clinical and Medical Affairs | 407.1K | — | 938.9K | — | 193.9K | 12.0K | 1.55M | 60.50% | ↗ |
| 55 | 2015 | Eric d'Esparbes Senior Vice President and Chief Financial Officer | 383.8K | — | 486.0K | — | 182.6K | 9.0K | 1.06M | 45.79% | ↗ |
| 56 | 2014 | Rick E Winningham Former Chief Executive Officer | 511.9K | — | 5.65M | — | 383.9K | 500.00 | 6.55M | 86.31% | ↗ |
| 57 | 2014 | Michael W. Aguiar President and Chief Executive Officer | 557.2K | — | 3.56M | — | 437.5K | 500.00 | 4.56M | 78.18% | ↗ |
| 58 | 2014 | Michael W. Aguiar President and Chief Executive Officer | 557.2K | — | 3.56M | — | 437.5K | 500.00 | 4.56M | 78.18% | ↗ |
| 59 | 2014 | Mathai Mammen Former Senior Vice President, Research Development | 342.1K | — | 2.57M | — | — | 500.00 | 2.91M | 88.23% | ↗ |
| 60 | 2014 | Leonard M. Blum Former Senior Vice President and Chief Commercial Officer | 321.6K | — | 2.57M | — | — | 500.00 | 2.89M | 88.86% | ↗ |
| 61 | 2014 | Eric d'Esparbes Senior Vice President and Chief Financial Officer | 87.8K | — | 1.88M | — | 80.0K | 15.3K | 2.07M | 91.14% | ↗ |
| 62 | 2014 | George B. Abercrombie Senior Vice President | 219.2K | — | 293.2K | 1.22M | 170.0K | 500.00 | 1.90M | 79.49% | ↗ |
| 63 | 2014 | George B. Abercrombie Senior Vice President and Chief Commercial Officer | 219.2K | — | 293.2K | 1.22M | 170.0K | 500.00 | 1.90M | 79.49% | ↗ |
| 64 | 2014 | Theodore J. Witek, Jr. | 192.9K | — | — | 1.16M | 140.9K | 500.00 | 1.49M | 77.57% | ↗ |
| 65 | 2014 | Theodore J. Witek, Jr. Senior Vice President and Chief Scientific Officer Clinical and Medical Affairs | 192.9K | — | — | 1.16M | 140.9K | 500.00 | 1.49M | 77.57% | ↗ |
| 66 | 2013 | Rick E. Winningham Chief Executive Officer | 857.9K | 129.0K | 244.4K | — | 516.0K | 500.00 | 1.75M | 13.98% | ↗ |
| 67 | 2013 | Rick E Winningham Former Chief Executive Officer | 857.9K | 129.0K | 244.4K | — | 516.0K | 500.00 | 1.75M | 13.98% | ↗ |
| 68 | 2013 | Michael W. Aguiar Senior Vice President, Chief Financial Officer | 457.0K | 58.4K | 111.1K | — | 229.1K | 500.00 | 856.2K | 12.98% | ↗ |
| 69 | 2013 | Michael W. Aguiar President and Chief Executive Officer | 457.0K | 58.4K | 111.1K | — | 229.1K | 500.00 | 856.2K | 12.98% | ↗ |
| 70 | 2013 | Michael W. Aguiar President and Chief Executive Officer | 457.0K | 58.4K | 111.1K | — | 229.1K | 500.00 | 856.2K | 12.98% | ↗ |
| 71 | 2013 | Mathai Mammen Former Senior Vice President, Research Development | 428.1K | 56.9K | 111.1K | — | 214.7K | 500.00 | 811.3K | 13.69% | ↗ |
| 72 | 2013 | Mathai Mammen Senior Vice President, Research Development | 428.1K | 56.9K | 111.1K | — | 214.7K | 500.00 | 811.3K | 13.69% | ↗ |
| 73 | 2013 | Bradford J. Shafer Senior Vice President, General Counsel | 413.8K | 52.9K | 111.1K | — | 207.4K | 500.00 | 785.7K | 14.14% | ↗ |
| 74 | 2013 | Leonard M. Blum Senior Vice President and Chief Commercial Officer | 415.7K | 41.7K | 111.1K | — | 208.4K | 500.00 | 777.4K | 14.29% | ↗ |
| 75 | 2013 | Leonard M. Blum Former Senior Vice President and Chief Commercial Officer | 415.7K | 41.7K | 111.1K | — | 208.4K | 500.00 | 777.4K | 14.29% | ↗ |
| 76 | 2012 | Rick E Winningham Former Chief Executive Officer | 833.3K | 35.1K | 199.2K | — | 450.9K | 500.00 | 1.52M | 13.11% | ↗ |
| 77 | 2012 | Rick E. Winningham Chief Executive Officer | 833.3K | 35.1K | 199.2K | — | 450.9K | 500.00 | 1.52M | 13.11% | ↗ |
| 78 | 2012 | Michael W. Aguiar President and Chief Executive Officer | 441.7K | 20.7K | 90.6K | — | 199.3K | 500.00 | 752.8K | 12.03% | ↗ |
| 79 | 2012 | Michael W. Aguiar Senior Vice President, Chief Financial Officer | 441.7K | 20.7K | 90.6K | — | 199.3K | 500.00 | 752.8K | 12.03% | ↗ |
| 80 | 2012 | Mathai Mammen Former Senior Vice President, Research Development | 411.9K | 19.2K | 90.6K | — | 185.8K | 500.00 | 708.0K | 12.79% | ↗ |
| 81 | 2012 | Mathai Mammen Senior Vice President, Research Early Clinical Development | 411.9K | 19.2K | 90.6K | — | 185.8K | 500.00 | 708.0K | 12.79% | ↗ |
| 82 | 2012 | Mathai Mammen Senior Vice President, Research Development | 411.9K | 19.2K | 90.6K | — | 185.8K | 500.00 | 708.0K | 12.79% | ↗ |
| 83 | 2012 | Leonard M. Blum Former Senior Vice President and Chief Commercial Officer | 403.6K | 15.9K | 90.6K | — | 182.1K | 500.00 | 692.7K | 13.07% | ↗ |
| 84 | 2012 | Leonard M. Blum Senior Vice President and Chief Commercial Officer | 403.6K | 15.9K | 90.6K | — | 182.1K | 500.00 | 692.7K | 13.07% | ↗ |
| 85 | 2012 | Bradford J. Shafer Senior Vice President, General Counsel | 400.8K | 14.2K | 90.6K | — | 180.8K | 500.00 | 686.9K | 13.18% | ↗ |
| 86 | 2011 | Rick E. Winningham Chief Executive Officer | 812.8K | — | 5.44M | — | 586.5K | 1.0K | 6.84M | 79.53% | ↗ |
| 87 | 2011 | Rick E Winningham Chief Executive Officer | 812.8K | — | 5.44M | — | 586.5K | 1.0K | 6.84M | 79.53% | ↗ |
| 88 | 2011 | Michael W. Aguiar Senior Vice President, Chief Financial Officer | 428.7K | — | 2.47M | — | 257.9K | 843.00 | 3.16M | 78.25% | ↗ |
| 89 | 2011 | Mathai Mammen Senior Vice President, Research Early Clinical Development | 399.2K | — | 2.47M | — | 240.5K | 843.00 | 3.11M | 79.43% | ↗ |
| 90 | 2011 | Mathai Mammen Senior Vice President, Research Development | 399.2K | — | 2.47M | — | 240.5K | 843.00 | 3.11M | 79.43% | ↗ |
| 91 | 2011 | Leonard M. Blum Senior Vice President and Chief Commercial Officer | 391.9K | — | 2.47M | — | 235.7K | 843.00 | 3.10M | 79.74% | ↗ |
| 92 | 2011 | Bradford J. Shafer Senior Vice President, General Counsel | 389.2K | — | 2.47M | — | 234.1K | 843.00 | 3.10M | 79.85% | ↗ |
| 93 | 2010 | Rick E Winningham Chief Executive Officer | 792.8K | 26.2K | 556.6K | — | 570.8K | — | 1.95M | 28.60% | ↗ |
| 94 | 2010 | Rick E. Winningham Chief Executive Officer | 792.8K | 26.2K | 556.6K | — | 570.8K | — | 1.95M | 28.60% | ↗ |
| 95 | 2010 | Michael W. Aguiar Senior Vice President, Chief Financial Officer | 400.6K | 20.8K | 253.0K | — | 249.2K | — | 923.6K | 27.39% | ↗ |
| 96 | 2010 | Bradford J. Shafer Senior Vice President, General Counsel | 378.4K | 10.4K | 253.0K | — | 227.3K | — | 869.1K | 29.11% | ↗ |
| 97 | 2010 | Leonard M. Blum Senior Vice President and Chief Commercial Officer | 381.1K | — | 253.0K | — | 228.8K | — | 862.9K | 29.32% | ↗ |
| 98 | 2010 | Mathai Mammen Senior Vice President, Research Early Clinical Development | 356.4K | 10.5K | 253.0K | — | 228.0K | — | 847.8K | 29.84% | ↗ |
| 99 | 2009 | Rick E Winningham Chief Executive Officer | 791.5K | — | 1.17M | — | 336.9K | 148.00 | 2.30M | 50.94% | ↗ |
| 100 | 2009 | Leonard M. Blum Senior Vice President and Chief Commercial Officer | 376.8K | — | 512.8K | — | 128.4K | 507.6K | 1.53M | 33.61% | ↗ |
| 101 | 2009 | Mathai Mammen Senior Vice President, Research | 327.5K | — | 542.1K | — | 321.1K | 148.00 | 1.19M | 45.52% | ↗ |
| 102 | 2009 | Mathai Mammen Senior Vice President, Research Early Clinical Development | 327.5K | — | 542.1K | — | 321.1K | 148.00 | 1.19M | 45.52% | ↗ |
| 103 | 2009 | Michael W. Aguiar Senior Vice President, Chief Financial Officer | 381.6K | — | 542.1K | — | 130.1K | 148.00 | 1.05M | 51.43% | ↗ |
| 104 | 2009 | Bradford J. Shafer Senior Vice President, General Counsel | 373.2K | — | 542.1K | — | 127.5K | 148.00 | 1.04M | 51.98% | ↗ |
| 105 | 2008 | Mathai Mammen Senior Vice President, Research | 299.8K | 21.6K | 217.8K | — | 292.9K | — | 1.81M | 12.02% | ↗ |
| 106 | 2008 | Mathai Mammen Senior Vice President, Research Early Clinical Development | 299.8K | 21.6K | 217.8K | — | 292.9K | — | 1.81M | 12.02% | ↗ |
| 107 | 2008 | Rick E Winningham Chief Executive Officer | 775.4K | 88.8K | 457.7K | — | 272.0K | — | 1.59M | 28.72% | ↗ |
| 108 | 2008 | Leonard M. Blum Senior Vice President and Chief Commercial Officer | 367.7K | 26.5K | 320.2K | 618.3K | 103.2K | 65.1K | 1.50M | 62.53% | ↗ |
| 109 | 2008 | Michael W. Aguiar Senior Vice President, Chief Financial Officer | 370.2K | 33.9K | 462.0K | — | 104.0K | — | 1.47M | 31.52% | ↗ |
| 110 | 2008 | Mathai Mammen Senior Vice President, Research Early Clinical Development | 299.8K | 21.6K | 47.3K | 493.4K | 292.9K | — | 1.16M | 46.81% | ↗ |
| 111 | 2008 | Leonard M. Blum Senior Vice President and Chief Commercial Officer | 367.7K | 26.5K | 269.5K | — | 103.2K | 65.1K | 1.08M | 24.96% | ↗ |
| 112 | 2008 | Arthur L. Campbell Former Senior Vice President, Technical Operations | 323.6K | 7.1K | 4.9K | — | — | 275.5K | 749.9K | 0.65% | ↗ |
| 113 | 2008 | Bradford J. Shafer Senior Vice President, General Counsel | 351.8K | 32.2K | 106.4K | — | 98.8K | — | 589.3K | 18.06% | ↗ |
| 114 | 2007 | Rick E Winningham Chief Executive Officer | 751.6K | — | — | — | 283.0K | 36.4K | 2.26M | 0.00% | ↗ |
| 115 | 2007 | Michael W. Aguiar Senior Vice President, Chief Financial Officer | 355.4K | — | — | — | 107.1K | — | 1.66M | 0.00% | ↗ |
| 116 | 2007 | Arthur L. Campbell Senior Vice President, Technical Operations | 351.7K | — | — | 370.2K | 105.9K | — | 827.8K | 44.72% | ↗ |
| 117 | 2007 | Arthur L. Campbell Former Senior Vice President, Technical Operations | 351.7K | — | — | — | 105.9K | — | 827.8K | 0.00% | ↗ |
| 118 | 2006 | Rick E Winningham Chief Executive Officer | 716.2K | — | — | 1.27M | 332.4K | — | 2.32M | 54.66% | ↗ |
| 119 | 2006 | Rick E Winningham Chief Executive Officer | 716.2K | — | — | — | 332.4K | — | 2.32M | 0.00% | ↗ |
| 120 | 2006 | Michael W. Aguiar Senior Vice President, Chief Financial Officer | 335.9K | — | 293.9K | 696.0K | 93.4K | — | 1.42M | 69.65% | ↗ |
| 121 | 2006 | Michael W. Aguiar Senior Vice President, Chief Financial Officer | 335.9K | — | 293.9K | — | 93.4K | — | 1.42M | 20.71% | ↗ |
| 122 | 2006 | Patrick P.A. Humphrey | 373.9K | — | — | 625.7K | 138.8K | — | 1.14M | 54.88% | ↗ |
| 123 | 2006 | Bradford J. Shafer Senior Vice President, General Counsel | 322.1K | — | — | 375.4K | 89.7K | 105.6K | 894.8K | 41.96% | ↗ |
| 124 | 2006 | Bradford J. Shafer Senior Vice President, General Counsel | 322.1K | — | — | — | 89.7K | 105.6K | 892.8K | 0.00% | ↗ |
| 125 | 2006 | Michael M. Kitt | 347.6K | — | — | 392.8K | 97.1K | — | 839.5K | 46.78% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Pavel Raifeld | Chief Executive Officer & Director | 1M | male |
| Stephen Basso | Chief Financial Officer | 716.8K | male |
| Marianne Zhen | Chief Accounting Officer & Secretary | 691.3K | female |
| David Altarac | Chief Medical Officer of IST | — | — |
| Marcie Cain | Chief People Officer | — | female |
| Patricia Drake | Chief Commercial Officer-Innoviva Specialty Therapeutics, Inc. | — | female |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Political Trading Activity (25M)
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
| Transaction Date | Disclosed | Representative | District | Owner | Type | Amount | Link |
|---|---|---|---|---|---|---|---|
| 2025-03-25 | 2025-04-23 | George Whitesides | CA27 | Spouse | Sale Full | $250,001 - $500,000 | ↗ |
| 2025-03-25 | 2025-04-23 | George Whitesides | CA27 | Spouse | Sale (Full) | $250,001 - $500,000 | ↗ |
| 2025-03-24 | 2025-04-23 | George Whitesides | CA27 | — | Sale (Full) | $50,001 - $100,000 | ↗ |
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for INVA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
